

**National HIV Curriculum 3rd Edition: Summary of CME Credit, CNE Contact Hours, CE Contact Hours, and Pharmacology CE for Advanced Practice Nurses as of 9/1/23**

Title	Lesson	Lesson CME/CNE/CE	Lesson Pharma. CE for APN	QB CME/CNE/CE	QB Pharma. CE for APN
<b>Module 1 Screening and Diagnosis</b>					
Epidemiology of HIV	1	1.00	0.00	1.50	0.00
HIV Screening Recommendations	2	1.00	0.00	1.00	0.00
HIV Diagnostic Testing	3	1.50	0.00	1.00	0.00
Acute and Recent HIV Infection	4	1.00	0.00	1.00	0.00
Linkage to HIV Care	5	1.00	0.00	0.50	0.00
		<b>5.50</b>	<b>0.00</b>	<b>5.00</b>	<b>0.00</b>
<b>Module 2 Basic HIV Primary Care</b>					
Initial Evaluation	1	1.00	0.00	1.00	0.00
Oral Manifestations	2	1.00	1.00	1.00	1.00
Cutaneous Manifestations	3	1.50	1.50	1.00	1.00
Immunizations in Adults	4	2.00	2.00	1.50	1.50
Primary Care Management	5	2.00	0.00	1.50	0.00
Screening for Mental Health Conditions	6	1.50	0.00	0.50	0.00
Substance Use Disorders	7	2.00	0.00	1.00	0.00
Retention in HIV Care	8	1.00	0.00	0.50	0.00
		<b>12.00</b>	<b>4.50</b>	<b>8.00</b>	<b>3.50</b>
<b>Module 3 Antiretroviral Therapy</b>					
Antiretroviral Medications and Initial Therapy	1	1.50	1.50	1.00	1.00
Adverse Effects of Antiretroviral Medications	2	1.50	1.50	1.00	1.00
Drug Interactions with Antiretroviral Medications	3	1.50	1.50	1.00	1.00
Switching or Simplifying Antiretroviral Therapy	4	1.50	1.50	1.00	1.00
Evaluation and Management of Virologic Failure	5	2.00	2.00	1.00	1.00
		<b>8.00</b>	<b>8.00</b>	<b>5.00</b>	<b>5.00</b>

**National HIV Curriculum 3rd Edition: Summary of CME Credit, CNE Contact Hours, CE Contact Hours, and Pharmacology CE for Advanced Practice Nurses as of 9/1/23**

Title	Lesson	Lesson CME/CNE/CE	Lesson Pharma. CE for APN	QB CME/CNE/CE	QB Pharma. CE for APN
<b>Module 4 Co-Occuring Conditions</b>					
Latent Tuberculosis Infection	1	1.00	0.00	1.00	0.00
Opportunistic Infections: Prevention	2	1.00	1.00	1.50	1.50
Opportunistic Infections: Treatment	3	2.00	2.00	2.00	2.00
Sexually Transmitted Infections	4	2.00	2.00	2.00	2.00
Hepatitis B Coinfection	5	1.50	1.50	1.00	1.00
Hepatitis C Coinfection	6	1.50	1.50	1.00	1.00
		<b>9.00</b>	<b>8.00</b>	<b>8.50</b>	<b>7.50</b>
<b>Module 5 Prevention of HIV</b>					
Preventing Perinatal HIV Transmission	1	1.50	1.50	1.50	1.50
Preventing HIV Transmission in Persons with HIV	2	1.00	0.00	1.00	0.00
Occupational Postexposure Prophylaxis	3	1.00	1.00	1.00	1.00
Nonoccupational Postexposure Prophylaxis	4	1.50	1.50	1.00	1.00
HIV Preexposure Prophylaxis (PrEP)	5	2.00	2.00	1.00	1.00
		<b>7.00</b>	<b>6.00</b>	<b>5.50</b>	<b>4.50</b>
<b>Module 6 Key Populations</b>					
HIV in Infants and Children	1	1.50	1.50	1.00	1.00
HIV in Adolescents and Young Adults	2	1.50	1.50	1.00	1.00
HIV In Women	3	1.50	1.50	1.00	1.00
HIV in Older Adults	4	1.00	1.00	1.00	1.00
HIV and Corrections	5	1.00	0.00	1.00	0.00
HIV in Racial and Ethnic Minority Populations	6	1.00	0.00	0.50	0.00
HIV in Sexual and Gender Minority Populations	7	2.00	2.00	1.00	1.00
HIV-2 Infection	8	1.00	1.00	1.00	1.00
		<b>10.50</b>	<b>8.50</b>	<b>7.50</b>	<b>6.00</b>
<b>Combined CE total as of 9/1/23:</b>	<b>37</b>	<b>52.00</b>	<b>39.00</b>	<b>39.50</b>	<b>26.50</b>
<b>91.5 CME/CNE/CE</b> <b>65.5 Pharmacology CE</b>	<b>Lessons</b>	<b>CE</b>	<b>Pharma CE</b>	<b>QB CE</b>	<b>QB Pharm CE</b>